Hyderabad, Feb. 4 -- Rainbow Children's Heart Institute on Wednesday reported one of the world's first successful clinical applications of direct fetal immunotherapy to treat immune-mediated fetal myocarditis, a rare and life-threatening heart condition affecting unborn babies.
The landmark clinical experience, involving five foetuses treated between 21 and 27 weeks of gestation, has been published in JACC: Case Reports, placing the Hyderabad-based centre among a select few globally to demonstrate success with this advanced in-utero intervention, the Institute said in a release here.
The condition occurs when maternal autoimmune antibodies, commonly associated with disorders such as Sjogren's syndrome, cross the placenta and damage the de...